Repurposing Public 23Q2

This data release contains the most recent PRISM Repurposing screens: Repurposing-1M. All Repurposing-1M [REP1M] compounds (1280 REP1M) were screened in the PRISM assay at a dose of 2.5 μM with a 5-day treatment against 906 cancer cell lines (859 of them passed quality checks -QC- for all tested compound with two high quality replicates). Two PRISM cell line collections were used in the assay: PR500A, which includes only adherent cell lines, and PR500B, which has adherent and suspension cell lines. Together, these PRISM cell line collections form the PR1000 cell line collection. All compounds were run in triplicate, and each plate contained positive (Bortezomib, 20μM) and negative (DMSO) controls. The screen can be considered an extension of the PRISM Repurposing Primary Screen, with PR500A mainly covering the existing cell line panel, while PR500B extends the cell line collection with new subtypes and lineages. For the assay details, please refer to Corsello et al., 2020 (doi.org/10.1038/s43018-019-0018-6) and https://www.theprismlab.org.

本次发布的数据集涵盖最新的PRISM重定位筛选实验集：Repurposing-1M。所有Repurposing-1M（简称REP1M）化合物（共计1280种）均以2.5 μM的给药浓度、5天孵育时长，在PRISM检测体系中针对906株癌细胞系完成筛选；其中859株细胞系通过了所有受试化合物的质量验证（QC），且设置了两次高质量生物学重复。本次检测共使用两套PRISM细胞系库：仅包含贴壁细胞系的PR500A，以及同时涵盖贴壁与悬浮细胞系的PR500B。两套细胞系库共同构成PR1000总细胞系库。所有化合物均设置三次技术重复，且每块检测板均包含阳性对照（硼替佐米，20 μM）与阴性对照（二甲基亚砜，DMSO）。本次筛选可视为PRISM重定位原初筛选的延伸：PR500A主要覆盖现有细胞系面板，而PR500B则通过新增细胞亚型与谱系类型拓展了细胞系库。若需了解检测详细方法，请参考Corsello等人2020年发表的研究（doi.org/10.1038/s43018-019-0018-6）及PRISM实验室官方网站https://www.theprismlab.org。